ArticleNature communications2014
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 296 citations in OpenAlex.
- Differential targeting of the nucleosome surface and superhelical crevice sites with Ru and Os organometallic agents.Nucleic acids research · 2026Article
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
- A Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System.ACS chemical biology · 2026Article
- DNA Noncovalent Interactions of Dinuclear ηChemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Review of the Most Important Research Trends in Potential Chemotherapeutics Based on Coordination Compounds of Ruthenium, Rhodium and Iridium.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)-Arene Compound RAPTA-T for Triple-NegativeInternational journal of molecular sciences · 2025Article
- Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy forInternational journal of molecular sciences · 2025Review
- The Role of Metallodrugs in Enhancing Neuroendocrine Neoplasm Therapies: The Promising Anticancer Potential of Ruthenium-Based Complexes.Molecules (Basel, Switzerland) · 2025Review
- Bilosomal Encapsulation of Binuclear Phosphino Ru(II)-Cu(II) Compounds Enhances Their Selectivity and Activity toward Lung and Prostate Cancers.Journal of medicinal chemistry · 2025Article
- Antiproliferative Water-Soluble Mono- and Binuclear Ruthenium Complexes with Pyridone-Imidazole Ligands.International journal of molecular sciences · 2025Article
- Viral peptide conjugates for metal-warhead delivery to chromatin.RSC advances · 2024Article
- Metals in Cancer Research: Beyond Platinum Metallodrugs.ACS central science · 2024Review
- Enantiomeric Complexes Based on Ruthenium(III) and 2,2'-Biimidazole: X-ray Structure and Magnetic Properties.Molecules (Basel, Switzerland) · 2023Article
- Dichloro Ru(II)-ACS pharmacology & translational science · 2023Review
- New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents.Pharmaceutics · 2023Article
- Triazolyl- vs Pyridyl-FunctionalizedACS organic & inorganic Au · 2022Article
- Arene Variation of Highly Cytotoxic Tridentate Naphthoquinone-Based Ruthenium(II) Complexes and In-Depth In Vitro Studies.Pharmaceutics · 2022Article
- Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model.Inorganic chemistry · 2021Article
- Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer.Pharmaceutics · 2021Article
- Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies.Inorganic chemistry · 2021Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruthenium compounds have become promising alternatives to platinum drugs by displaying specific activities against different cancers and favourable toxicity and clearance properties. Nonetheless, their molecular targeting and mechanism of action are poorly understood. Here we study two prototypical ruthenium-arene agents-the cytotoxic antiprimary tumour compound [(η(6)-p-cymene)Ru(ethylene-diamine)Cl]PF6 and the relatively non-cytotoxic antimetastasis compound [(η(6)-p-cymene)Ru(1,3,5-triaza-7-phosphaadamantane)Cl2]-and discover that the former targets the DNA of chromatin, while the latter preferentially forms adducts on the histone proteins. Using a novel 'atom-to-cell' approach, we establish the basis for the surprisingly site-selective adduct formation behaviour and distinct cellular impact of these two chemically similar anticancer agents, which suggests that the cytotoxic effects arise largely from DNA lesions, whereas the protein adducts may be linked to the other therapeutic activities. Our study shows promise for developing new ruthenium drugs, via ligand-based modulation of DNA versus protein binding and thus cytotoxic potential, to target distinguishing epigenetic features of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.